128 related articles for article (PubMed ID: 35470464)
21. Genetic polymorphisms in PXR and NF-κB1 influence susceptibility to anti-tuberculosis drug-induced liver injury.
Zhang J; Zhao Z; Bai H; Wang M; Jiao L; Peng W; Wu T; Liu T; Chen H; Song X; Wu L; Hu X; Wu Q; Zhou J; Song J; Lyv M; Ying B
PLoS One; 2019; 14(9):e0222033. PubMed ID: 31490979
[TBL] [Abstract][Full Text] [Related]
22. The association between BACH1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in a Chinese cohort.
Zhang H; Qian H; Tao B; Yang M; Gong J; Yi H; Tang S
Infect Genet Evol; 2018 Dec; 66():217-221. PubMed ID: 30316884
[TBL] [Abstract][Full Text] [Related]
23. Polymorphisms in drug metabolism genes as a risk factor for first-line anti-tuberculosis drug-induced liver injury.
Meitei HN; Pandey A; Haobam R
Mol Biol Rep; 2023 Mar; 50(3):2893-2900. PubMed ID: 36562936
[TBL] [Abstract][Full Text] [Related]
24. Interaction between the HIF-1α gene rs1957757 polymorphism and CpG island methylation in the promoter region is associated with the risk of anti-tuberculosis drug-induced liver injury in humans: A case-control study.
Chong Y; Zhu H; Ren Q; Ma X; Feng F
J Clin Pharm Ther; 2022 Jul; 47(7):948-955. PubMed ID: 35218216
[TBL] [Abstract][Full Text] [Related]
25. NAT2 slow acetylator is associated with anti-tuberculosis drug-induced liver injury severity in indonesian population.
Yuliwulandari R; Prayuni K; Susilowati RW; M Sofro AS; Tokunaga K; Shin JG
Pharmacogenomics; 2019 Dec; 20(18):1303-1311. PubMed ID: 31699005
[No Abstract] [Full Text] [Related]
26. Relationship between common telomere length-related genetic variations, telomere length, and risk of antituberculosis drug-induced hepatotoxicity in Chinese Han population: As assessed for causality using the updated Roussel Uclaf Causality Assessment Method.
Chen X; Hao Z; Pan H; Liu W; Lu L; Zhang M; He X; Yi H; Tang S
Fundam Clin Pharmacol; 2023 Aug; 37(4):858-867. PubMed ID: 36855016
[TBL] [Abstract][Full Text] [Related]
27. Relevance of
Cheng F; Qiu CC; Jiang XG; Wu T; Zhang Q; Chen X; Zheng SL; Liu SD; Ye XC; Shi JC
Pharmacogenomics; 2024 Jan; 25(1):21-28. PubMed ID: 38131213
[TBL] [Abstract][Full Text] [Related]
28. Polymorphism of PXR gene associated with the increased risk of drug-induced liver injury in Indonesian pulmonary tuberculosis patients.
Zazuli Z; Barliana MI; Mulyani UA; Perwitasari DA; Ng H; Abdulah R
J Clin Pharm Ther; 2015 Dec; 40(6):680-4. PubMed ID: 26417664
[TBL] [Abstract][Full Text] [Related]
29. Association of
Wang N; Chen X; Hao Z; Yi H; Tang S
Xenobiotica; 2022 May; 52(5):527-533. PubMed ID: 35735268
[TBL] [Abstract][Full Text] [Related]
30. The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis.
Zhang M; Wang S; Wilffert B; Tong R; van Soolingen D; van den Hof S; Alffenaar JW
Br J Clin Pharmacol; 2018 Dec; 84(12):2747-2760. PubMed ID: 30047605
[TBL] [Abstract][Full Text] [Related]
31. Role of polymorphic bile salt export pump (BSEP, ABCB11) transporters in anti-tuberculosis drug-induced liver injury in a Chinese cohort.
Chen R; Wang J; Tang S; Zhang Y; Lv X; Wu S; Yang Z; Xia Y; Chen D; Zhan S
Sci Rep; 2016 Jun; 6():27750. PubMed ID: 27293027
[TBL] [Abstract][Full Text] [Related]
32. Heme oxygenase-1 and hemopexin gene polymorphisms and the risk of anti-tuberculosis drug-induced hepatotoxicity in China.
Liu W; Lu L; Pan H; He X; Zhang M; Wang N; Zhu J; Yi H; Tang S
Pharmacogenomics; 2022 May; 23(7):431-441. PubMed ID: 35470713
[No Abstract] [Full Text] [Related]
33. N-acetyltransferase and cytochrome P450 2E1 gene polymorphisms and susceptibility to antituberculosis drug hepatotoxicity in an Indian population.
Mishra S; Daschakraborty S; Shukla P; Kapoor P; Aggarwal R
Natl Med J India; 2013; 26(5):260-5. PubMed ID: 25017831
[TBL] [Abstract][Full Text] [Related]
34. rs1800796 of the IL6 gene is associated with increased risk for anti-tuberculosis drug-induced hepatotoxicity in Chinese Han children.
Li Y; Tang H; Qi H; Shen C; Sun L; Li J; Xu F; Jiao W; Yang X; Shen A
Tuberculosis (Edinb); 2018 Jul; 111():71-77. PubMed ID: 30029918
[TBL] [Abstract][Full Text] [Related]
35. Antituberculosis drug-induced liver injury in chronic hepatitis and cirrhosis.
Park WB; Kim W; Lee KL; Yim JJ; Kim M; Jung YJ; Kim NJ; Kim DH; Kim YJ; Yoon JH; Oh MD; Lee HS
J Infect; 2010 Oct; 61(4):323-9. PubMed ID: 20670648
[TBL] [Abstract][Full Text] [Related]
36. The role of hepatitis B infection in anti-tuberculosis drug-induced liver injury: a meta-analysis of cohort studies.
Zheng J; Guo MH; Peng HW; Cai XL; Wu YL; Peng XE
Epidemiol Infect; 2020 Nov; 148():e290. PubMed ID: 33222713
[TBL] [Abstract][Full Text] [Related]
37. Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury.
Huang YS; Su WJ; Huang YH; Chen CY; Chang FY; Lin HC; Lee SD
J Hepatol; 2007 Jul; 47(1):128-34. PubMed ID: 17400324
[TBL] [Abstract][Full Text] [Related]
38. Genetic Polymorphisms in Antioxidant Enzymes Modulate the Susceptibility of Idiosyncratic Antituberculous Drug-Induced Liver Injury and Treatment Outcomes in Patients with Tuberculosis.
Sun Q; Sha W; Liu HP; Wang P; Liu ZB; Sun WW; Xiao HP
Pharmacotherapy; 2020 Jan; 40(1):4-16. PubMed ID: 31742742
[TBL] [Abstract][Full Text] [Related]
39. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis.
Ben Mahmoud L; Ghozzi H; Kamoun A; Hakim A; Hachicha H; Hammami S; Sahnoun Z; Zalila N; Makni H; Zeghal K
Pathol Biol (Paris); 2012 Oct; 60(5):324-30. PubMed ID: 21856096
[TBL] [Abstract][Full Text] [Related]
40. Is the Prophylactic Use of Hepatoprotectants Necessary in Anti-Tuberculosis Treatment?
Xu L; Zhang F; Xu C; Liu KG; Wu W; Tian YX
Chemotherapy; 2017; 62(5):269-278. PubMed ID: 28490012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
